ViaCell, Cord Blood settle marketing dispute

By E. Janene Geiss

Philadelphia, Oct. 27 - ViaCell, Inc. and Cord Blood Registry Systems, Inc. announced Thursday they have settled the dispute that has prompted still-pending litigation.

The dispute related to marketing and advertising claims made by each company, according to company news releases.

Under the terms of the agreement, the companies have agreed to dismiss all outstanding claims and counter claims in the litigation, officials said.

No payment will be made. Other terms were not disclosed, officials said.

Cambridge, Mass.-based ViaCell is a biotechnology company focused on enabling widespread use of human cells in medicine.

San Bruno, Calif.-based Cord Blood Registry has been collecting and processing newborn stem cells for family banking since 1992.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.